Literature DB >> 1430001

Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology.

E K Mberu1, D K Muhia, W M Watkins.   

Abstract

A new high-performance liquid chromatographic assay for the measurement of halofantrine and desbutylhalofantrine in plasma and whole blood is described. The method involves a smaller sample volume, simplified sample pre-treatment and a shorter run-time, and is adaptable to the measurement of samples dried onto filter paper strips. Using this method, which is both selective and sensitive, plasma concentration versus time profiles for both substances have been investigated following a single oral dose (500 mg) of halofantrine hydrochloride to a healthy adult volunteer. In addition, a clinical study designed to evaluate the disposition and elimination of the two compounds in children with non-severe falciparum malaria is in progress.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430001     DOI: 10.1016/0378-4347(92)80461-x

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine.

Authors:  I D Lightbown; J P Lambert; G Edwards; S J Coker
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Effect of a single oral dose of Fansidar on the pharmacokinetics of halofantrine in healthy volunteers: a preliminary report.

Authors:  F W Hombhanje
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

3.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

4.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

5.  Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria.

Authors:  W M Watkins; P A Winstanley; E K Mberu; G Kokwaro; S A Murphy; C J Newton; I Mwangi; D Forster; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

7.  Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice.

Authors:  Vanessa C F Mosqueira; Philippe M Loiseau; Christian Bories; Philippe Legrand; Jean-Philippe Devissaguet; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

8.  World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.

Authors:  Karen I Barnes; Niklas Lindegardh; Olumide Ogundahunsi; Piero Olliaro; Christopher V Plowe; Milijaona Randrianarivelojosia; Grace O Gbotosho; William M Watkins; Carol H Sibley; Nicholas J White
Journal:  Malar J       Date:  2007-09-06       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.